Daniel Naul
Family Medicine · Baton Rouge, LANPI 1003234915
Payments from drug & device makers
Across 197 payments — averaging $14.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$686
- Pfizer$496
- GSK$456
- Amgen$131
- Novo Nordisk$124
- Johnson & Johnson$119
- plus $815 from 23 others
What the payments were for
- Food & beverage$2,79199%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 51 | $686 |
| Pfizer | 29 | $496 |
| GSK | 30 | $456 |
| Amgen | 9 | $131 |
| Novo Nordisk | 9 | $124 |
| Johnson & Johnson | 9 | $119 |
| Lilly USA, LLC | 6 | $85 |
| Kowa Pharmaceuticals America, Inc. | 7 | $84 |
| Abbott | 5 | $75 |
| Boehringer Ingelheim | 5 | $75 |
| AstraZeneca | 5 | $62 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 5 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Eisai Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $26 |
| Genentech USA, Inc. | 2 | $26 |
| Merck | 2 | $25 |
| Biogen | 1 | $21 |
| Nevro Corp. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Bioventus LLC | 1 | $15 |
| Qiagen, LLC | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$2,826 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 174 | $170,616 |
| JardianceEmpagliflozin | 81 | $78,573 |
| JanuviaSitagliptin Phosphate | 83 | $69,891 |
| EliquisApixaban | 77 | $50,383 |
| MounjaroTirzepatide | 46 | $48,189 |
| TradjentaLinagliptin | 25 | $26,764 |
| TrulicityDulaglutide | 22 | $21,736 |
| MyrbetriqMirabegron | 39 | $19,028 |
| XareltoRivaroxaban | 16 | $13,547 |
| FarxigaDapagliflozin Propanediol | 20 | $12,793 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,711 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,798 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,384 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 35 | $7,230 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $6,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $124 | $170,616174 claims |
| Boehringer IngelheimJardiance, Tradjenta | $75 | $105,337106 claims |
| Lilly USA, LLCMounjaro, Trulicity | $85 | $69,92568 claims |
| MerckJanuvia | $25 | $69,89183 claims |
| PfizerEliquis | $496 | $50,38377 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $456 | $28,73977 claims |
| Johnson & JohnsonXarelto | $119 | $13,54716 claims |
| AstraZenecaFarxiga | $62 | $12,79320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Baton Rouge
- Christine SmithBaton Rouge$185K
- Kevin DibenedettoBaton Rouge$80K
- Stan MaysBaton Rouge$15K
- Myles JaynesBaton Rouge$15K
- Yushen LeeBaton Rouge$14K
- Gerald BarberBaton Rouge$14K
- Vincent NguyenBaton Rouge$13K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.